Gå direkt till huvudinnehållet

Schizofreni

Senast uppdaterad: Senast reviderad:
Sakkunnig:


Definition:
Schizofreni är en allvarlig psykisk sjukdom som präglas av hallucinationer och vanföreställningar, och som leder till social undandragenhet och sviktande funktion både socialt och yrkesmässigt.
Förekomst:
Livstidsprevalensen har beräknats till cirka 0,4–0,7 % i systematiska översikter.
Symtom:
Vanliga symtom är vanföreställningar, hallucinationer, tankeförloppsstörningar, desorganiserat eller katatont beteende och social undandragenhet.
Kliniska fynd:
Inga somatiska patognoma fynd, men högre risk för diabetes och hjärt-kärlsjukdom i denna grupp är viktigt att vara uppmärksam på.
Diagnostik:
Standardiserade diagnostiska intervjuer. Uteslutande av bakomliggande somatisk orsak genom somatisk undersökning, blodprover, DT eller MRT samt EEG.
Behandling:
Antipsykotika, psykoterapi och psykosociala insatser.
  1. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063-72. PubMed  
  2. Schultz, SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician 2007; 75: 1821-9. PMID: 17619525 PubMed  
  3. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review. BMC Psychiatry. 2015;15:193. Published 2015 Aug 12. PMID: 26263900 PubMed  
  4. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005 May;2(5):e141. PMID: 15916472 PubMed  
  5. Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One. 2018;13(4):e0195687. PMID: 29649252 PubMed  
  6. Nationella riktlinjer för vård och stöd vid schizofreni och schizofreniliknande tillstånd. Socialstyrelsen 2018. www.socialstyrelsen.se  
  7. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 67-76. PubMed  
  8. Wahlman Laurell B (redaktör). Schizofreni. Kliniska riktlinjer för utredning och behandling. Svenska psykiatriska föreningen/Gothia Förlag; 2009 www.svenskpsykiatri.se  
  9. Hilker R, Helenius D, Fagerlund B, et al. Heritability of Schizophrenia and Schizophrenia Spectrum Based on the Nationwide Danish Twin Register. Biol Psychiatry. 2018;83(6):492–498. PMID: 28987712 PubMed  
  10. Johannessen JO. Schizofreni - omfang og betydning. Tidsskr Nor Lægeforen 2002; 122: 2011-4. PubMed  
  11. A Systematic Review of Developmental Features Across Childhood. Harv Rev Psychiatry. 2016 Mar-Apr;24(2):104-17. pmid: 26954595 PubMed  
  12. Allen et al. 2008. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene Database. Nat Genet 40(7): 823-34.
  13. Ripke S, Sanders AR, Kendler KS, et al. Genome-wide association study identifies five new schizophrenia loci. Nature Genetics 2011; : doi:10.1038/ng.940. DOI  
  14. Lingjærde O. Nevrobiologiske funn ved schizofreni. Tidsskr Nor Lægeforen 2002; 122: 2123-7. PubMed  
  15. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1. PubMed  
  16. Goldman AL, Pezawas L, Mattay VS, et al. Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Arch Gen Psychiatry 2009; 66: 467. PubMed  
  17. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry 2000; 57:637. PubMed  
  18. Bermanzohn PC, Porto L, Arlow PB, Pollack S, Stronger R, Siris SC. Hierarchical diagnosis in chronic schizophrenia; a clinical study of co-occurring syndromes. Schizophr Bull 2000; 26: 517 - 25. PubMed  
  19. McGorry P. Posttraumatic stress disorder postpsychosis. J Nerv Ment Dis 1993; 181: 766. PubMed  
  20. Kliniska riktlinjer - Att förebygga och handlägga metabol risk hos patienter med allvarlig psykisk sjukdom. Svenska psykiatriska föreningen, Svenska Psykiatriska Föreningen, Svenska Föreningen för Barn- och Ungdomspsykiatri, Svensk Förening för Allmänmedicin Svensk Förening för Diabetologi Svensk Internmedicinsk Förening, Svenska Cardiologföreningen, Svensk Förening för Obesitasforskning. Hämtad 2020-03-30 medibas.se  
  21. Cannon M, Jones P. Neuroepidemiology: schizophrenia. J Neurol Neurosurg Psychiatry 1996; 61: 604-13. PubMed  
  22. Insel BJ. Metarnal iron defeciency andt he risk of schizophrenia in offspring. Arch Gen Psychiatry 2008; 65: 1136-44. PubMed  
  23. Bernstein CN, Hitchon CA, Bolton JM, et al. Increased burden of psychiatric disorders in inflammatory bowel disease. Inflamm Bowel Dis. 2019 Jan 10;25(2):360-368 . pmid:29986021 PubMed  
  24. Krabbendam L, van Os J. Schizophrenia and urbanicity: a major environmental influence – conditional on genetic risk. Schizophr Bull 2005; 31: 795–9.
  25. Cantor-Graae E, Selten JP. Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry. 2005; Jan;162(1): :12-24. doi:PMID: 15625195 PubMed  
  26. Tienari P. Interations between generic vulnerability and family environment: the Finnish adoptive family study of schizophrenia. Acta Scandinaiva Psychiatrica 84; 1991; 460-465.
  27. Byrne M, Agerbo E, Ewald H, Eaton WW, Mortensen PB. Parental age and risk of schizophrenia: a case-control study. Arch Gen Psychiatry 2003; 60: 673 - 8. PubMed  
  28. Kendall T, Hollis C, Stafford M, Taylor C. Recognition and management of psychosis and schizophrenia in children and young people: summary of NICE guidance. BMJ 2013; 346: f150. BMJ (DOI)  
  29. Gorczynski P, Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst Rev. 2010 May 12;(5):CD004412. doi: 10.1002/14651858.CD004412.pub2. Pmid 20464730 www.cochranelibrary.com  
  30. Dauwan M, Begemann MJ, Heringa SM, et al. Exercise Improves Clinical Symptoms, Quality of Life, Global Functioning, and Depression in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull 2016 May; 42(3): 588-99. pmid:26547223 www.ncbi.nlm.nih.gov  
  31. Åtgärder för att stödja personer med schizofreni att förändra ohälsosamma levnadsvanor, SBU 2016 www.sbu.se  
  32. Frankenburg FR. Schizophrenia. Medscape, last updated Oct 06, 2015. emedicine.medscape.com  
  33. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-73. PMID: 19861668 PubMed  
  34. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. JAMA Psychiatry. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. 2017 Jul 1;74(7):686-693. PMID: 8593216.
  35. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013 Jun 26. doi:10.1016/S0140-6736(13)60733-3 DOI  
  36. Leucht S, Leucht C, Huhn M, et al. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry 2017. pmid:28541090 PubMed  
  37. Zhu Y, Krause M, Huhn M, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry. 2017;4(9):694–705. PMID: 28736102 PubMed  
  38. Läkemedelsverket: Läkemedelsbehandling vid schizofreni – behandlingsrekommendation (2013) www.lakemedelsverket.se  
  39. SBU: Schizofreni – Läkemedelsbehandling, patientens delaktighet och vårdens organisation – En systematisk litteraturöversikt (2012) www.sbu.se  
  40. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35. New England Journal of Medicine  
  41. Petersen L, Jeppesen P, Thorup A, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005; 331: 602. British Medical Journal  
  42. Wu RR, Jin H, Gao K, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012; 169: 813-21. PMID: 22711171 PubMed  
  43. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2005. PMID: 15846598 PubMed  
  44. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database of Systematic Reviews 2012; 4: CD008712. Cochrane (DOI)  
  45. Bighelli I, Huhn M, Schneider-Thoma J, et al. Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. BMC Psychiatry 2018; 18(1): 380. pmid:30514268 PubMed  
  46. Penney D, Sauvé G, Mendelson D, et al. Immediate and Sustained Outcomes and Moderators Associated With Metacognitive Training for Psychosis A Systematic Review and Meta-analysis. JAMA Psyciatry 2022. pmid:35320347 PubMed  
  47. De Silva MJ, Cooper S, Li HL, et al. Effect of psychosocial interventions on social functioning in depression and schizophrenia: meta-analysis. Br J Psychiatry. 2013 Apr;202(4):253-60. doi: 10.1192/bjp.bp.112.118018. DOI  
  48. Markström Urban, Bejerholm Ulrika, Svensson Bengt, Bergmark Magnus.Implementeringen av nationella riktlinjer för psykosociala insatser vid schizofreni Implementeringen av nationella riktlinjer för psykosociala insatser vid schizofreni – exemplen IPS och ACT. 2015 www.cepi.lu.se  
  49. Pekkala E, Merinder L. Psychoeducation for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. PMID: 12076455 PubMed  
  50. Amminger GP, Schäfer MR, Schlögelhofer , et al. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun 2015; 6: 7934. doi:10.1038/ncomms8934 DOI  
  51. Hafner H, der Heiden W. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 1999; 249 (suppl 4): 14 - 26.
  52. Melle I, Larsen TK, Haahr U, et al. Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch.Gen.Psychiatry 2004; 61: 143-150. PMID: 14757590 PubMed  
  53. Melle I, Johannesen JO, Friis S, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 2006; mai.
  54. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000; 28: 325-34. PubMed  
  55. De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr Res 2001; 47: 127-34. PubMed  
  56. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187: 9-20. British Journal of Psychiatry  
  57. Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD006391. DOI: 10.1002/14651858.CD006391.pub2. DOI  
  58. Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M, for the INDIGO Study Group. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet 2009; 373: 408-15. PubMed  
  59. Hegarty JD, Baldessarini RJ, Tohen M, Watermaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 2994; 151: 1409-16. American Journal of Psychiatry  
  60. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organisation ten-country study. Psychol Med 1992; monograph supplement 20: 1-97.
  61. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212 - 7. PubMed  
  62. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-31. PubMed  
  63. Tiihonen J, Mittendorfer-Rutz E, Torniainen M, et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: An observational follow-up study. Am J Psychiatry 2015. PMID: 26651392 PubMed  
  • Mussie Msghina, docent och specialist i psykiatri, Örebro Universitet.